These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22560614)

  • 21. H-Ras signaling and K-Ras signaling are differentially dependent on endocytosis.
    Roy S; Wyse B; Hancock JF
    Mol Cell Biol; 2002 Jul; 22(14):5128-40. PubMed ID: 12077341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of B-Raf and regulation of the mitogen-activated protein kinase pathway by the G(o) alpha chain.
    Antonelli V; Bernasconi F; Wong YH; Vallar L
    Mol Biol Cell; 2000 Apr; 11(4):1129-42. PubMed ID: 10749919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.
    Chatelle CV; Hövermann D; Müller A; Wagner HJ; Weber W; Radziwill G
    Sci Rep; 2016 Mar; 6():23713. PubMed ID: 27025703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
    Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
    Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural snapshots of RAF kinase interactions.
    Rezaei Adariani S; Buchholzer M; Akbarzadeh M; Nakhaei-Rad S; Dvorsky R; Ahmadian MR
    Biochem Soc Trans; 2018 Dec; 46(6):1393-1406. PubMed ID: 30381334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
    Henry JR; Kaufman MD; Peng SB; Ahn YM; Caldwell TM; Vogeti L; Telikepalli H; Lu WP; Hood MM; Rutkoski TJ; Smith BD; Vogeti S; Miller D; Wise SC; Chun L; Zhang X; Zhang Y; Kays L; Hipskind PA; Wrobleski AD; Lobb KL; Clay JM; Cohen JD; Walgren JL; McCann D; Patel P; Clawson DK; Guo S; Manglicmot D; Groshong C; Logan C; Starling JJ; Flynn DL
    J Med Chem; 2015 May; 58(10):4165-79. PubMed ID: 25965804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
    Kaplan FM; Kugel CH; Dadpey N; Shao Y; Abel EV; Aplin AE
    J Biol Chem; 2012 Dec; 287(50):41797-807. PubMed ID: 23076151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenic K-ras segregates at spatially distinct plasma membrane signaling platforms according to its phosphorylation status.
    Barceló C; Paco N; Beckett AJ; Alvarez-Moya B; Garrido E; Gelabert M; Tebar F; Jaumot M; Prior I; Agell N
    J Cell Sci; 2013 Oct; 126(Pt 20):4553-9. PubMed ID: 23943869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Raf kinases in cancer-roles and therapeutic opportunities.
    Maurer G; Tarkowski B; Baccarini M
    Oncogene; 2011 Aug; 30(32):3477-88. PubMed ID: 21577205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Active Ras induces heterodimerization of cRaf and BRaf.
    Weber CK; Slupsky JR; Kalmes HA; Rapp UR
    Cancer Res; 2001 May; 61(9):3595-8. PubMed ID: 11325826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3.
    Shalom-Feuerstein R; Plowman SJ; Rotblat B; Ariotti N; Tian T; Hancock JF; Kloog Y
    Cancer Res; 2008 Aug; 68(16):6608-16. PubMed ID: 18701484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
    Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nucleophosmin and nucleolin regulate K-Ras plasma membrane interactions and MAPK signal transduction.
    Inder KL; Lau C; Loo D; Chaudhary N; Goodall A; Martin S; Jones A; van der Hoeven D; Parton RG; Hill MM; Hancock JF
    J Biol Chem; 2009 Oct; 284(41):28410-28419. PubMed ID: 19661056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protomer selectivity of type II RAF inhibitors within the RAS/RAF complex.
    Vasta JD; Michaud A; Zimprich CA; Beck MT; Swiatnicki MR; Zegzouti H; Thomas MR; Wilkinson J; Crapster JA; Robers MB
    Cell Chem Biol; 2023 Nov; 30(11):1354-1365.e6. PubMed ID: 37643616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
    Collisson EA; De A; Suzuki H; Gambhir SS; Kolodney MS
    Cancer Res; 2003 Sep; 63(18):5669-73. PubMed ID: 14522881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF.
    Yuan J; Ng WH; Yap J; Chia B; Huang X; Wang M; Hu J
    J Biol Chem; 2018 Sep; 293(37):14276-14284. PubMed ID: 30030377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.
    Leung GP; Feng T; Sigoillot FD; Geyer FC; Shirley MD; Ruddy DA; Rakiec DP; Freeman AK; Engelman JA; Jaskelioff M; Stuart DD
    Mol Cancer Res; 2019 Jan; 17(1):199-211. PubMed ID: 30201825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C-Raf is required for the initiation of lung cancer by K-Ras(G12D).
    Karreth FA; Frese KK; DeNicola GM; Baccarini M; Tuveson DA
    Cancer Discov; 2011 Jul; 1(2):128-36. PubMed ID: 22043453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
    Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
    Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.